Jan 23
Aravax closes Series B round with US$42m to accelerate Phase 2 development for peanut allergy therapy
23 Jan 2024: Aravax, a clinical stage biotechnology company developing the first rationally designed and precisely targeted...
top of page
Developing safe, convenient, disease-modifying treatments for food allergies.
.jpg)
News
bottom of page